Kimberly Irvine is a two-time breast cancer survivor, author, and CEO and Founder of Kimberly Jewett Consulting, Inc. KJC provides strategic guidance and insight from a patient and care-partner perspective to pharmaceutical and bio-tech companies, ensuring the patient voice is centric in the landscape of product development and commercialization, while collaborating with patient advocacy groups as valued partners. Irvine received her initial diagnosis when she was only 31 years old, and again at 35. Currently, doctors have declared her disease-free. Irvine is a passionate patient advocate and thought leader in the oncology space – educating, inspiring and empowering other patients, care-partners, and their support community to “be their own best advocates.” Irvine attributes her survivorship to her strong faith, hope, and resilience to overcome adversity.
Carolyn R. (“Bo”) Aldigé is the Founder and CEO of the Prevent Cancer Foundation, a national non-profit organization she started in 1985 in memory of her father. Today, the Foundation is recognized as a leader in the fight against cancer through prevention and early detection and receives the highest ratings from all charity “watchdogs”. Aldigé serves on the External Advisory Board of MD Anderson Cancer Center, the boards of directors of Friends of Cancer Research and the Intercultural Cancer Council, and the advisory boards of Project ECHO and Stand Up to Cancer. She is chairman of Global Action for Cancer Patients and vice-chairman of the Global Lung Cancer Coalition. Aldigé has been honored for her public service by the National Cancer Institute and numerous NGOs, including AACR and ASCO.
Deneen Vojta, M.D. is Executive Vice President, Global Research & Development, a division of UnitedHealth Group that is focused on accelerating the design, execution and scaling of disruptive programs, products and services to improve health care quality, reduce care costs, more effectively engage consumers in their health and help modernize the health system.
Dr. Vojta has 25 years of executive experience in health system and health plan administration. Dr. Vojta has served as a board member of non-profit health care institutions, and earned numerous federal and foundation grants to investigate complex health care concerns.
Dr. Okuda is a clinician-scientist and professor specializing in multiple sclerosis within the Department of Neurology and Neurotherapeutics at UT Southwestern Medical Center in Dallas, Texas.
Dr. Okuda leads the neuroinnovation program that focuses on end-to-end innovative approaches involving the design, creation and implementation of tools aimed at improving the evaluation, diagnosis, and management of patients with neurological disease. His work involves translating technological innovations for next generation healthcare by designing novel connections between patients and providers, developing new diagnostic and clinical surveillance metrics, transforming medical decision-making, and challenging existing norms. He continues to be actively involved in extreme healthcare initiatives aimed at delivering care more accurately, efficiently, and intelligently.
Dr. Okuda is a Diplomate of The American Board of Psychiatry and Neurology, Inc., Fellow of the American Academy of Neurology, Fellow of the American Neurological Association, and member of the American Academy of Neurology Committees on Neuro-imaging and Ethics.
Dr. Geri Lynn Utter, PsyD. is a Clinical Psychologist who specializes in working with individuals diagnosed with both substance use disorders and severe mental illness. Throughout her career, she has conducted psychological evaluations for the Courts on incarcerated individuals in an effort to ensure they receive the appropriate mental health and drug and alcohol treatment during and post release from prison. Currently, Dr. Utter works on the Medical Affairs team at Orexo Pharmaceuticals, a specialty pharmaceutical company dedicated to developing and manufacturing medication designed to help individuals with opioid dependence. Over the past year, Orexo has expanded its’ portfolio into the Digital Therapeutics space with digital technologies designed to support individuals with depression, problematic drinking and opioid use disorder. Dr. Utter is passionate about working with individuals and families who have been impacted by drug and alcohol addiction as both her mother and father have struggled with addiction throughout their lives. In April of 2020, she released her first book, Mainlining Philly: Survival, Hope and Resisting Drug Addiction which came from her desire to share her story and instill hope. The book is based largely on experiences and challenges that she faced in life due to her parents’ struggles with drugs and alcohol abuse and also encompasses a short Addiction Handbook designed to offer psychoeducation about addiction and mental illness. In an effort to overcome the stigma associated with addiction and other mental health issues, Dr. Utter continues to provide education and spread awareness. Website: www.drgerilynnutter.com.
Philip Rutherford is the Chief Operating Officer at Faces & Voices of Recovery. He is a recovery coach, a passionate member of the Recovery Community and possesses a self-described Doctorate from the school of Hard Knocks. As COO, he is responsible for multiple lines of business within the Faces & Voices ecosystem. Phil is credited with a significant role in conception, design, launch and facilitation of the Recovery Data Platform (RDP). This cloud-based platform is the first of its kind and has quickly become a valuable asset in longitudinal data collection for Peer-Based Services. Phil has a BA in Psychology with a specialization in Substance Use Disorders. Phil’s prior experience as Director at a Recovery Community Organization offered front-row seat into the world of Peer Based Recovery Supports. Prior to that, he spent most of his career in corporate sales, marketing, and management at Microsoft, Micron Electronics, and companies within the Taylor Corporation. Phil is an active member of the Recovery community and has considerable experience in the areas of Substance Use Disorders, Recovery, Re-entry, and Cultural Competency.
Aaron Laxton is the Director of Development and Therapist with Assisted Recovery Center of America, LLC. He is a graduate of the Saint Louis University, School of Social Work, where he received his Master of Social Work with an emphasis on Community and Organization. He is a licensed Master of Social Work in the State of Missouri. Aaron has worked in the social services for more than a decade in the St. Louis metropolitan area. Aaron’s values his own personal lived experience with addiction as the most valuable tool he has, as he works with peers, individuals with OUD/oSUD and families.
A visionary leader with 3 decades of global healthcare client
oversight, Jeff is an expert in rare diseases with strong advocacy ties
to more than 50 major associations. With capabilities in advertising,
digital experience, medical communications and brand strategy, he
has built and sold 3 medical education agencies, and founded HVH
Precision Analytics.
Additionally, Jeff has executed global rare disease launches for 8
brands, launched 4 new divisions within Havas, and completed 6
acquisitions in the past 3 years. He holds a bachelor’s degree in
economics and business from Muhlenberg College in Pennsylvania.
Schibsted Growth is a part of Schibsted Media Group, and is one of the most active corporate VCs in the Nordics, focusing on Nordic entrepreneurs but with global ambitions. Schibsted Growth invests in and manages a portfolio of +40 fast-growing digital companies, with previous investments such as Lendo, Mindler, Insurello, etc. Schibsted has a history of building strong consumer brands and has the past 2 years placed a larger focus on healthtech and patient-centric digital services. The latest investments within the healthtech space was Hjemmelegene and Mindler.
Adam Fine is a co-founder and CEO of Windham Venture Partners. Adam is currently Director at Coravin, GlySens, CuraSeal and HelpAround, Board Observer to SpineView, MC10, Holaira and VytronUS. Adam is a mentor in Blueprint Health, a healthcare IT accelerator in NYC. Prior to Windham, Adam was VP & GM at I-many, Inc., an enterprise software company. Prior to joining I-many, Adam was a New Business Development Analyst at Cordis Corporation, a Johnson & Johnson company focused on interventional vascular devices such as stents. In that capacity, Adam worked on a range of licenses, acquisitions, divestments, as well as strategic investments with Johnson & Johnson Development Corporation (JJDC), J&J’s strategic venture arm. Prior to J&J, Adam was a research analyst at Coopers & Lybrand’s Integrated Healthcare Consulting practice.